Rivals’ disappointing results in asthma trial drag down shares of AnaptysBio

Disappointing clinical trial results from Sanofi and Regeneron raise questions about the future role that certain drugs might have in treating asthma and other inflammatory related diseases.
Source: Kristoffer Tripplaar/Sipa via AP

Sanofi (SNY) and Regeneron Pharmaceuticals () said Friday that a monoclonal antibody drug targeting a protein called IL-33 provided no additional benefit to asthma patients when added to the already approved drug Dupixent.

You're reading a preview, sign up to read more.

More from STAT

STAT4 min readSociety
Opinion: It’s Time To Change The Definition Of ‘Health’
Rather than pursuing the "absence" of disease, we need a more inclusive definition of health — one that works for more people.
STAT4 min read
Opinion: State Drug Importation Programs Will Work With The FDA, Not Outside Of It
State programs can use the global pharmaceutical supply chain to relieve the sometimes crushing financial burden of drug treatments — at least until we have an effective national approach to…
STAT5 min readSociety
Opinion: I Wanted To Try Medical Marijuana. Why Couldn’t My Doctors Help Me?
Until we make it easier to study the effects of #medicalmarijuana and #cannabis, and train doctors about its benefits and risks, people who could benefit from it will continue to…